Effect of glucocorticoid (triamcinolone acetonide) pretreatment in a murine penetrating keratoplasty and suture model

Cornea

Volumn 31, Issue 12, 2012, Pages 1468-1475

  Cho, Yang K ^a,b   Uehara, Hironori ^a   Young, Jason R ^a   Archer, Bonnie ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

angiogenesis; glucocorticoid pretreatment; penetrating keratoplasty; triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DRUG EFFICACY; INTRAOCULAR PRESSURE; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PENETRATING KERATOPLASTY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; GRAFT SURVIVAL; INTRAOCULAR PRESSURE; KERATITIS; KERATOPLASTY, PENETRATING; LYMPHANGIOGENESIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PREMEDICATION; SUTURE TECHNIQUES; TRIAMCINOLONE ACETONIDE;

EID: 84870245003     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182473356     Document Type: Article

References (39)

1. Lam H, Dana MR. Corneal graft rejection. Int Ophthalmol Clin. 2009;49:31-41.
2. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992;110:1392-1403.
3. Streilein JW, Yamada J, Dana MR, et al. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472-1475. (Pubitemid 29234906)
4. Santos LN, de Moura LR, Fernandes BF, et al. Histopathological study of delayed regraft after corneal graft failure. Cornea. 2011;30:167-170.
5. Baradaran-Rafii A, Karimian F, Javadi M, et al. Corneal graft rejection: incidence and risk factors. Iran J Ophthalmic Res. 2007;2:7-14.
6. Weisbrod DJ, Sit M, Naor J, et al. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea. 2003;22:429-434. (Pubitemid 36759037)
7. Athanasiadis I, De Wit D, Tsatsos M, et al. Subconjunctival injection of triamcinolone acetonide in the management of corneal graft rejection and new vessels. J Clin Pharmacol. [published online ahead of print April 19, 2011] doi:10.1177/0091270011400073.
8. Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after nonhighrisk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2001;239:514-521. (Pubitemid 32725422)
9. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25:286-290.
10. Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol. 2008;28:223-232. (Pubitemid 351627108)
11. Unal M, Yücel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92:1411-1414.
12. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593. (Pubitemid 19185963)
13. Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol. 2011;129:445-452.
14. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaBactivated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007;171:1058-1065. (Pubitemid 47441002)
15. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005-1016. (Pubitemid 351412293)
16. Murata M, Shimizu S, Horiuchi S, et al. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2006;244:205-209.
17. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315. (Pubitemid 28131129)
18. Boneham GC, Collin HB. Steroid inhibition of limbal blood and lymphatic vascular cell growth. Curr Eye Res. 1995;14:1-10.
19. Flynn TH, Ohbayashi M, Dawson M, et al. The effect of perioperative allergic conjunctivitis on corneal lymphangiogenesis after corneal transplantation. Br J Ophthalmol. 2011;95:1451-1456.
20. Niederkorn JY. High-risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol. 2010;10:493-497.
21. Fu H, Larkin DF, George AJ. Immune modulation in corneal transplantation. Transplant Rev (Orlando). 2008;22:105-115. (Pubitemid 351384331)
22. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:330-343.
23. Cursiefen C, Maruyama K, Jackson DG, et al. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea. 2006;25:443-447. (Pubitemid 44620130)
24. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050. (Pubitemid 38544126)
25. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
26. Nguyen NX, Seitz B, Martus P, et al. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol. 2007;144:318-319. (Pubitemid 47094708)
27. Frank S, Hübner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995;270:12607-12613.
28. Planck SR, Ansel JC, Huang XN, et al. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocul Immunol Inflamm. 1997;5:95-100. (Pubitemid 27299997)
29. Klintworth GK. Corneal Angiogenesis: A Comprehensive Critical Review. Vol. 16. New York, NY: Springer Verlag; 1991.
30. Gupta D, Illingworth C. Treatment for corneal neovascularization: a review. Cornea. 2011;30:927-938.
31. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. II. Studies on the effect of leukocytic elimination on corneal vascularization. Am J Pathol. 1975;81:531-544.
32. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673. (Pubitemid 38998863)
33. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128:192-197. (Pubitemid 29379772)
34. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184:535-539.
35. Kagaya F, Usui T, Kamiya K, et al. Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea. 2002;21:200-202. (Pubitemid 34188791)
36. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:2411-2417.
37. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica. 2010;224(suppl 1):25-30.
38. Negi AK, Browning AC, Vernon SA. Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: randomized controlled trial. J Cataract Refract Surg. 2006;32:468-474.
39. Dieleman M, Wubbels RJ, van Kooten-Noordzij M, et al. Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery. J Cataract Refract Surg. 2011;37:1589-1597.